Carcinogenesis Advance Access published online on December 19, 2003
Carcinogenesis, doi:10.1093/carcin/bgh049
© 2003 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CANCER BIOLOGY
1 Division of Cell Biology, floor 9, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping University, Linköping, Sweden
* Corresponding author. E-mail: karfr{at}ibk.liu.se.
Received 20 August 2003
; revised 19 November 2003
; accepted 30 November 2003
Colorectal cancer is a multi-step process characterized by a sequence of genetic alterations in cell growth regulatory genes, such as adenomatous polyposis coli, KRAS, p53 and DCC genes. In the present study, mutation analysis was performed with SSCA/direct sequencing of the hot-spot regions in exons 11 and 15 for the BRAF gene and exons 1-2 for the KRAS gene in 130 primary colorectal cancer tumors and correlated to clinico-pathological and mutational data. We also performed mutation analysis of the corresponding conserved regions in the ARAF and RAF-1 genes. Mutations in the BRAF and KRAS genes were found in 11.5% and 40% of the tumors, respectively. One germline exonic and nine germline intronic genetic variants were found in the ARAF and RAF-1 genes. All of the BRAF mutations were located in the kinase domain of the conserved region 3 in exon 15 of the BRAF gene. One novel somatic mutation was also identified in the BRAF gene. The majority of the BRAF mutations were found in the colon compared to rectal tumors (P=0.014). In agreement with others, a statistically significant correlation between BRAF mutations and microsatellite instability could be found. A negative correlation was also evident between mutations in the BRAF and KRAS genes which supports earlier studies where somatic mutations in these genes are mutually exclusive. Collectively, our results provide support for the idea that activation of the MAP kinase pathway, especially via BRAF and KRAS mutations, is of critical importance for the development of colorectal cancer.
colorectal cancer, BRAF, ARAF, RAF-1, MAPK pathway
Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas
2 Division of Cell Biology, floor 9, Department of Biomedicine and Surgery, Faculty of Health Sciences, Linköping University, Linköping, Sweden; Department of Natural Science and Biomedicine, University College of Health Sciences, Jönköping, Sweden
3 Department of Natural Science and Biomedicine, University College of Health Sciences, Jönköping, Sweden
4 Molecular Biology Laboratory, Strategic Development-LMÖ/IBK, University Hospital, Linköping, Sweden
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Mittmann, H.-J. Au, D. Tu, C. J. O'Callaghan, P. K. Isogai, C. S. Karapetis, J. R. Zalcberg, W. K. Evans, M. J. Moore, J. Siddiqui, et al. Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial J Natl Cancer Inst, September 2, 2009; 101(17): 1182 - 1192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al. K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. F. Calvisi, F. Pinna, F. Meloni, S. Ladu, R. Pellegrino, M. Sini, L. Daino, M. M. Simile, M. R. De Miglio, P. Virdis, et al. Dual-Specificity Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinase-Mediated Control of Growth in Human Hepatocellular Carcinoma Cancer Res., June 1, 2008; 68(11): 4192 - 4200. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hao, V. M. Muniz-Medina, H. Mehta, N. E. Thomas, V. Khazak, C. J. Der, and J. M. Shields Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth Mol. Cancer Ther., August 1, 2007; 6(8): 2220 - 2229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Yeh, V. Marsh, B. A. Bernat, J. Ballard, H. Colwell, R. J. Evans, J. Parry, D. Smith, B. J. Brandhuber, S. Gross, et al. Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor Clin. Cancer Res., March 1, 2007; 13(5): 1576 - 1583. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Grahn, M. Hmani-Aifa, K. Fransen, P. Soderkvist, and H.-J. Monstein Molecular identification of Helicobacter DNA present in human colorectal adenocarcinomas by 16S rDNA PCR amplification and pyrosequencing analysis J. Med. Microbiol., November 1, 2005; 54(11): 1031 - 1035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. L. Ince, A. M. Jubb, S. N. Holden, E. B. Holmgren, P. Tobin, M. Sridhar, H. I. Hurwitz, F. Kabbinavar, W. F. Novotny, K. J. Hillan, et al. Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab J Natl Cancer Inst, July 6, 2005; 97(13): 981 - 989. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Beach, A. O.-O. Chan, T.-T. Wu, J. A. White, J. S. Morris, S. Lunagomez, R. R. Broaddus, J.-P. J. Issa, S. R. Hamilton, and A. Rashid BRAF Mutations in Aberrant Crypt Foci and Hyperplastic Polyposis Am. J. Pathol., April 1, 2005; 166(4): 1069 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Oliveira, J. L. Westra, D. Arango, M. Ollikainen, E. Domingo, A. Ferreira, S. Velho, R. Niessen, K. Lagerstedt, P. Alhopuro, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status Hum. Mol. Genet., October 1, 2004; 13(19): 2303 - 2311. [Abstract] [Full Text] [PDF]
|
|